Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure
ConclusionThe 1-year survival advantage for FDC-ISDN/HYD compared with off-label combinations in adherent black Medicare beneficiaries with HF suggests a genuine difference between these medications and warrants prospective investigation.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Drugs & Pharmacology | Heart | Heart Failure | Hydralazine | Isosorbide Mononitrate | Medicare | Study